LIXTE Biotechnology Acquires Liora Technologies’ Proprietary Proton Therapy Platform for Cancer Treatment
LIXTE Biotechnology Holdings to Present at the Spartan Capital Investor Conference 2025, November 3
LIXTE Biotechnology Holdings Highlights Q4 2025 Priorities, Including Ongoing Advancement of Lead Candidate LB-100, Strategic Oncology Business Development and Acquisition Plans
Lixte Biotechnology (NASDAQ:LIXT) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
LIXTE Bio's Transformational Summer Marked by Leadership Updates, Scientific Progress, and Digital Treasury Strategy (NASDAQ:LIXT) [Yahoo! Finance]